Why we Should Opt Out of the Government's New Patient Database
By Edward Hockings,
The Guardian
| 01. 31. 2014
We have until March to opt out of the
care.data initiative. The ‘
theoretical risk’ that we might be re-identified from our personal data once it is made available to third parties is a compelling reason to opt-out. However, this is not the only reason. Care.data is part of a major legislative programme that includes the Clinical Research Practice Datalink (
CRPD) and the
100,000 genome project – through which whole-sequenced genomes will be put to commercial use. These major infrastructural developments have been accompanied by radical changes to privacy law that have resulted in a cultural shift in the governance of information.
These sweeping changes in privacy law were introduced without consultation, and the risks they entail will be borne by those whose medical records may be accessed without their consent. How did we get to this point? Fourteen years ago, written evidence by SmithKline Beecham to the Select Committee on Health, House of Commons, advanced the view that the “
NHS represents a singular but under-utilised resource for population genetics, and healthcare informatics more generally.”...
Related Articles
By Josie Ensor, The Times | 12.09.2025
A fertility start-up that promises to screen embryos to give would-be parents their “best baby” has come under fire for a “misuse of science”.
Nucleus Genomics describes its mission as “IVF for genetic optimisation”, offering advanced embryo testing that allows...
By Hannah Devlin, The Guardian | 12.06.2025
Couples undergoing IVF in the UK are exploiting an apparent legal loophole to rank their embryos based on genetic predictions of IQ, height and health, the Guardian has learned.
The controversial screening technique, which scores embryos based on their DNA...
By Frankie Fattorini, Pharmaceutical Technology | 12.02.2025
Próspera, a charter city on Roatán island in Honduras, hosts two biotechs working to combat ageing through gene therapy, as the organisation behind the city advertises its “flexible” regulatory jurisdiction to attract more developers.
In 2021, Minicircle set up a...
By Vardit Ravitsky, The Hastings Center | 12.04.2025
Embryo testing is advancing fast—but how far is too far? How and where do we draw the line between preventing disease and selecting for “desirable” traits? What are the ethical implications for parents, children, clinicians, and society at large? These...